GlaxoSmithKline Agrees to $105M Settlement
GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it marketed drugs for uses unapproved by federal regulators.
Lawsuits filed in 44 states and the District of Columbia alleged that the British drugmaker misrepresented the uses and qualities of its asthma drug Advair and the antidepressants Paxil and Wellbutrin.
The company isn't acknowledging any wrongdoing in the settlement announced Wednesday, but it agrees not to pay doctors to promote its products, make unapproved claims or use financial incentives that encourage salespeople to market drugs for uses not approved by the Food and Drug Administration.
GlaxoSmithKline settled a similar case with the federal government two years ago for a record $3 billion.
Its marketing practices also are under investigation in Britain, China and several other countries.